UA110943C2 - N-ацилсульфонамідні промотори апоптозу - Google Patents

N-ацилсульфонамідні промотори апоптозу

Info

Publication number
UA110943C2
UA110943C2 UAA201302545A UAA201302545A UA110943C2 UA 110943 C2 UA110943 C2 UA 110943C2 UA A201302545 A UAA201302545 A UA A201302545A UA A201302545 A UAA201302545 A UA A201302545A UA 110943 C2 UA110943 C2 UA 110943C2
Authority
UA
Ukraine
Prior art keywords
sulfonamideapoptosis
promoters
acyl
methods
bcl
Prior art date
Application number
UAA201302545A
Other languages
English (en)
Russian (ru)
Inventor
Роберт Брюс Діболд
Томас Джеро
Пол Гроувер
Шань Хуан
Стефанос Іоаннідіс
Клод Афона Огое
Джамал Карлос Саєх
Джеффрі Гілберт Варнес
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44528349&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA110943(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of UA110943C2 publication Critical patent/UA110943C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4

Abstract

Даний винахід стосується сполук формули (І) EMBED ISISServer Формула (І) та їх солей, фармацевтичних композицій, їх застосування та способів їх одержання. Ці сполуки інгібують активність Bcl-2 і/або Bcl-XL і можуть застосовуватися для лікування раку.
UAA201302545A 2010-08-06 2011-08-05 N-ацилсульфонамідні промотори апоптозу UA110943C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37164810P 2010-08-06 2010-08-06
US38417010P 2010-09-17 2010-09-17
PCT/GB2011/051484 WO2012017251A1 (en) 2010-08-06 2011-08-05 N-acylsulfonamide apoptosis promoters

Publications (1)

Publication Number Publication Date
UA110943C2 true UA110943C2 (uk) 2016-03-10

Family

ID=44528349

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201302545A UA110943C2 (uk) 2010-08-06 2011-08-05 N-ацилсульфонамідні промотори апоптозу

Country Status (40)

Country Link
US (4) US9018381B2 (uk)
EP (1) EP2601177B1 (uk)
JP (2) JP5886855B2 (uk)
KR (1) KR101840893B1 (uk)
CN (2) CN105367482B (uk)
AR (1) AR082573A1 (uk)
AU (2) AU2011287398C1 (uk)
BR (1) BR112013002914B1 (uk)
CA (1) CA2806190C (uk)
CL (2) CL2013000322A1 (uk)
CO (1) CO6670585A2 (uk)
CR (1) CR20130051A (uk)
CU (1) CU20130020A7 (uk)
CY (1) CY1120031T1 (uk)
DK (1) DK2601177T3 (uk)
EA (1) EA027788B1 (uk)
EC (1) ECSP13012426A (uk)
ES (1) ES2653936T3 (uk)
GT (1) GT201300034A (uk)
HK (1) HK1220967A1 (uk)
HR (1) HRP20171899T1 (uk)
HU (1) HUE035254T2 (uk)
IL (1) IL224218A (uk)
LT (1) LT2601177T (uk)
ME (1) ME02885B (uk)
MX (1) MX343043B (uk)
MY (1) MY165624A (uk)
NI (1) NI201300018A (uk)
NO (1) NO2601177T3 (uk)
NZ (1) NZ607794A (uk)
PL (1) PL2601177T3 (uk)
PT (1) PT2601177T (uk)
RS (1) RS56670B1 (uk)
SA (1) SA111320683B1 (uk)
SG (2) SG10201506194YA (uk)
SI (1) SI2601177T1 (uk)
TW (1) TWI535712B (uk)
UA (1) UA110943C2 (uk)
UY (1) UY33547A (uk)
WO (1) WO2012017251A1 (uk)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
SG11201505525UA (en) 2013-01-16 2015-08-28 Univ Michigan Bcl-2bcl-xl inhibitors and therapeutic methods using the same
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
PL3262071T3 (pl) * 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
WO2017101851A1 (en) * 2015-12-18 2017-06-22 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
KR20230156443A (ko) 2016-03-28 2023-11-14 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
US20200354336A9 (en) 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
US10689416B2 (en) 2017-12-30 2020-06-23 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
CN111801327B (zh) 2018-01-10 2024-02-09 里科瑞尔姆Ip控股有限责任公司 苯甲酰胺化合物
SG11202009933WA (en) 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
EP3787626B1 (en) 2018-04-30 2023-06-07 Unity Biotechnology, Inc. Phosphonamidates that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
CA3056878C (en) 2018-04-30 2021-03-30 Unity Biotechnology Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US10738042B2 (en) 2018-04-30 2020-08-11 Unity Biotechnology, Inc. Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US10717722B2 (en) 2018-06-13 2020-07-21 Unity Biotechnology, Inc. Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US11491168B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TW202021575A (zh) * 2018-08-17 2020-06-16 瑞典商阿斯特捷利康公司 樹枝狀體配製物
WO2020041406A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
EP4180422A4 (en) * 2020-07-10 2024-01-24 Jiangsu Hengrui Pharmaceuticals Co Ltd SULFONYL BENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PROCESS THEREOF AND USE THEREOF
JP2023538695A (ja) 2020-08-25 2023-09-08 上海森輝医薬有限公司 薬剤を担持する高分子及びその調製方法
AU2022240765A1 (en) 2021-03-19 2023-09-07 Eil Therapeutics, Inc. Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors
JP2024513227A (ja) 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Ｎｅｋ７阻害剤
WO2022226182A1 (en) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1154774B1 (en) 1999-02-10 2005-06-22 AstraZeneca AB Quinazoline derivatives as angiogenesis inhibitors
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
CN101175738B (zh) * 2005-05-12 2010-10-27 雅培制药有限公司 细胞凋亡促进剂
MX2008002019A (es) * 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
EP2094672B1 (en) * 2006-11-15 2013-05-29 Genentech, Inc. Arylsulfonamide compounds
JP5140154B2 (ja) * 2007-06-27 2013-02-06 アストラゼネカ・アクチエボラーグ ピラジノン誘導体および肺疾患の処置におけるそれらの使用
WO2009036035A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
EP3101019A1 (en) * 2008-12-05 2016-12-07 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SG175253A1 (en) 2009-05-26 2011-11-28 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物

Also Published As

Publication number Publication date
UY33547A (es) 2012-03-30
ECSP13012426A (es) 2013-03-28
EP2601177B1 (en) 2017-10-18
KR20130137599A (ko) 2013-12-17
CA2806190A1 (en) 2012-02-09
JP5886855B2 (ja) 2016-03-16
HUE035254T2 (en) 2018-05-02
DK2601177T3 (en) 2018-01-02
AU2011287398A1 (en) 2013-03-07
SG10201506194YA (en) 2015-09-29
PL2601177T3 (pl) 2018-02-28
ES2653936T3 (es) 2018-02-09
IL224218A (en) 2016-07-31
CN105367482B (zh) 2017-12-12
CL2015002372A1 (es) 2016-02-05
US20130310344A1 (en) 2013-11-21
LT2601177T (lt) 2017-12-27
MX343043B (es) 2016-10-21
CN105367482A (zh) 2016-03-02
CR20130051A (es) 2013-05-15
CN103153954B (zh) 2015-11-25
SA111320683B1 (ar) 2015-05-19
US9248140B2 (en) 2016-02-02
JP2016138109A (ja) 2016-08-04
AU2011287398C1 (en) 2017-08-24
US20160176906A1 (en) 2016-06-23
KR101840893B1 (ko) 2018-03-21
US20120035134A1 (en) 2012-02-09
SI2601177T1 (en) 2018-01-31
CN103153954A (zh) 2013-06-12
US9018381B2 (en) 2015-04-28
HRP20171899T1 (hr) 2018-01-26
BR112013002914B1 (pt) 2021-06-15
NI201300018A (es) 2013-10-16
JP2013532718A (ja) 2013-08-19
ME02885B (me) 2018-04-20
CL2013000322A1 (es) 2013-04-19
CU20130020A7 (es) 2013-07-31
CA2806190C (en) 2018-07-17
US20150328239A1 (en) 2015-11-19
EP2601177A1 (en) 2013-06-12
CY1120031T1 (el) 2018-12-12
MY165624A (en) 2018-04-18
EA027788B1 (ru) 2017-09-29
MX2013001494A (es) 2013-03-18
HK1220967A1 (zh) 2017-05-19
EA201300211A1 (ru) 2013-08-30
NO2601177T3 (uk) 2018-03-17
BR112013002914A2 (pt) 2019-01-08
TWI535712B (zh) 2016-06-01
WO2012017251A1 (en) 2012-02-09
TW201209049A (en) 2012-03-01
SG187178A1 (en) 2013-03-28
NZ607794A (en) 2015-03-27
AR082573A1 (es) 2012-12-19
CO6670585A2 (es) 2013-05-15
RS56670B1 (sr) 2018-03-30
AU2015210452A1 (en) 2015-09-03
AU2011287398B2 (en) 2015-08-27
GT201300034A (es) 2015-08-03
PT2601177T (pt) 2017-12-18

Similar Documents

Publication Publication Date Title
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
PH12017502141A1 (en) Compounds and their methods of use
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
PH12015501385A1 (en) Autotaxin inhibitors
MY162146A (en) Pharmaceutical composition
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
NZ706739A (en) Substituted benzene compounds
MX2013011922A (es) Compuestos de benceno substituido.
MY161088A (en) Agonists of gpr40
WO2013173441A3 (en) Enhancer of zeste homolog 2 inhibitors
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MY160241A (en) 5-alkynyl-pyrimidines
PH12015501609A1 (en) Phenicol antibacterials
MX343706B (es) Derivados heterocíclicos novedosos.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX362879B (es) Usos novedosos.
MX348127B (es) Derivados de quinazolinona como inhibidores del virus de la hepatitis c.
IN2015DN02109A (uk)
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.